Toru Ishikawa (Saiseikai Niigata Daini Byoin)
済生会新潟第二病院, 新潟市 · Japan
Editorial leadership for Journal of Current Chronic Diseases
Research interests
- Hepatocellular Carcinoma Liver Cirrhosis Portal Hypertension Hepatitis Ivr
Biography
Dr. Toru Ishikawa is affiliated with 済生会新潟第二病院 (Saiseikai Niigata Daini Hospital) in Niigata, Japan, where he has established a distinguished career in hepatology research. His scholarly contributions span over 66 indexed publications, with his most influential work being a 2023 large-scale real-world study comparing atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma, which has garnered 118 citations and significantly informed clinical practice in liver cancer treatment. Dr. Ishikawa's expertise in hepatocellular carcinoma and therapeutic outcomes has earned him recognition including the Hepatology Research Award from The Japan Society of Hepatology in 2003. His research continues to advance understanding of treatment strategies for liver diseases, particularly in the context of real-world clinical populations.
Selected publications
- Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 2023 cited 118×
- Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients 2023 cited 52×
- Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab 2023 cited 24×
- Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab 2022 cited 21×
- The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis 2022 cited 20×
- Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice 2024 cited 16×
Ranked by citation impact (Crossref) where available, newest otherwise · verified via ORCID.
Considering JCD for your work?
This journal is guided by Toru Ishikawa (済生会新潟第二病院, 新潟市) and a peer-review board of practising researchers. Open access, author-retained copyright (CC BY), and a clear editorial process.